The carbon footprint of external beam radiotherapy and its impact in health technology assessment.

Carbon footprint Health technology assessment Hypofractionation

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Sep 2024
Historique:
received: 30 03 2024
revised: 03 06 2024
accepted: 29 07 2024
medline: 1 9 2024
pubmed: 1 9 2024
entrez: 30 8 2024
Statut: epublish

Résumé

The major drivers of carbon dioxide (CO We describe the carbon footprint of four typical centers. We explore direct EBRT associated factors such as the impact of fractionation and use of MRI-LINAC, as well as indirect factors (e.g. patient rides). Treatment strategy related CO A typical EBRT treatment emits from 185 kgCO Carbon footprint of EBRT is not neglectable and could be mitigated. When safely feasible, hypofractionation is one of the main factors to decrease this impact. Taking into account CO

Sections du résumé

Background UNASSIGNED
The major drivers of carbon dioxide (CO
Material and methods UNASSIGNED
We describe the carbon footprint of four typical centers. We explore direct EBRT associated factors such as the impact of fractionation and use of MRI-LINAC, as well as indirect factors (e.g. patient rides). Treatment strategy related CO
Results UNASSIGNED
A typical EBRT treatment emits from 185 kgCO
Conclusion UNASSIGNED
Carbon footprint of EBRT is not neglectable and could be mitigated. When safely feasible, hypofractionation is one of the main factors to decrease this impact. Taking into account CO

Identifiants

pubmed: 39211397
doi: 10.1016/j.ctro.2024.100834
pii: S2405-6308(24)00111-3
pmc: PMC11359761
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100834

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):39-47
pubmed: 36309074
Am J Clin Pathol. 2021 Sep 8;156(4):540-549
pubmed: 33822876
Med J Aust. 2020 May;212(8):377-382
pubmed: 32304240
Int J Public Health. 2014 Jun;59(3):565-9
pubmed: 24752429
Sci Total Environ. 2010 Dec 1;409(1):33-42
pubmed: 20937518
Lancet Oncol. 2024 Jun;25(6):790-801
pubmed: 38821084
Lancet Reg Health West Pac. 2022 May 03;24:100459
pubmed: 35538935
Phys Med. 2023 Aug;112:102652
pubmed: 37552912
Environ Sci Technol. 2009 Mar 15;43(6):1689-95
pubmed: 19368158
JAMA Oncol. 2023 Mar 1;9(3):365-373
pubmed: 36633877
Int J Technol Assess Health Care. 2020 Apr;36(2):96-103
pubmed: 32340631
Clin Oncol (R Coll Radiol). 2022 Mar;34(3):e105-e106
pubmed: 34895991
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Radiother Oncol. 2022 Aug;173:306-312
pubmed: 35772576
Breast Cancer Res Treat. 2023 Jan;197(2):405-416
pubmed: 36396774
Eur Urol. 2023 May;83(5):463-471
pubmed: 36635108

Auteurs

Chloé Dupraz (C)

Oncologie médicale, Hospices civils de Lyon, France.

Coline Ducrot (C)

Département de Chirurgie Orthopédique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.

Benoit Allignet (B)

Département de Chirurgie Orthopédique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
Département de radiothérapie, Centre Léon Bérard, Lyon, France.
Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, Laboratoire CREATIS UMR 5220, U1294 Lyon, France.

Gregory Delpon (G)

Département de Physique Médicale, Institut de Cancérologie de l'Ouest, site Saint-Herblain, France.
Laboratoire SUBATECH, UMR 6457 CNRS-IN2P3, IMT Atlantique, Nantes, France.

Anthony Alexis (A)

Département de Physique Médicale, Institut de Cancérologie de l'Ouest, site Saint-Herblain, France.

Ariane Lapierre (A)

Service de radiothérapie, Hôpital lyon sud, Pierre bénite, France.

Stéphane Supiot (S)

Département de Radiothérapie, Institut de Cancérologie de l'Ouest, site Saint-Herblain, France.
Laboratoire US2B, CNRS UMR 6286, Université de Nantes, Nantes, France.

David Ali (D)

Centre de Radiothérapie de Versailles, France.

Max Piffoux (M)

Oncologie médicale, Hospices civils de Lyon, France.
Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon, France.

Classifications MeSH